Q3 Asset Management Invests $3.29 Million in SPDR S&P Biotech ETF (NYSEARCA:XBI) Stock

Q3 Asset Management purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,137,741 shares of the exchange traded fund’s stock, valued at approximately $3,285,000. SPDR S&P Biotech ETF comprises about 8.8% of Q3 Asset Management’s portfolio, making the stock its 3rd biggest position. Q3 Asset Management owned approximately 2.37% of SPDR S&P Biotech ETF as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of XBI. Quattro Financial Advisors LLC increased its stake in SPDR S&P Biotech ETF by 49.6% in the 4th quarter. Quattro Financial Advisors LLC now owns 374 shares of the exchange traded fund’s stock valued at $31,000 after buying an additional 124 shares during the period. Equitable Trust Co. increased its stake in SPDR S&P Biotech ETF by 2.6% in the 4th quarter. Equitable Trust Co. now owns 5,121 shares of the exchange traded fund’s stock valued at $367,000 after buying an additional 129 shares during the period. Perkins Coie Trust Co increased its stake in SPDR S&P Biotech ETF by 0.4% in the 4th quarter. Perkins Coie Trust Co now owns 34,621 shares of the exchange traded fund’s stock valued at $2,484,000 after buying an additional 136 shares during the period. RPG Investment Advisory LLC increased its stake in SPDR S&P Biotech ETF by 0.7% in the 4th quarter. RPG Investment Advisory LLC now owns 20,406 shares of the exchange traded fund’s stock valued at $1,464,000 after buying an additional 138 shares during the period. Finally, Mitchell Sinkler & Starr PA increased its stake in SPDR S&P Biotech ETF by 2.5% in the 4th quarter. Mitchell Sinkler & Starr PA now owns 6,190 shares of the exchange traded fund’s stock valued at $444,000 after buying an additional 150 shares during the period.

Shares of XBI opened at $84.32 on Friday. SPDR S&P Biotech ETF has a 1 year low of $64.38 and a 1 year high of $101.55.

COPYRIGHT VIOLATION WARNING: “Q3 Asset Management Invests $3.29 Million in SPDR S&P Biotech ETF (NYSEARCA:XBI) Stock” was published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/q3-asset-management-purchases-new-stake-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: Golden Cross

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.